Replies to post #37627 on Anavex Life Sciences Corp (AVXL)

[iandy]

you forgot how complex AD is and how complex the interrelation of the different receptor actions is with a new drug like 273, thats why information gathering quickly (i.e. an open adaptive trial) was used ..

The only way anyone is going to be interested in this drug is if they can demonstrate meaningful results. They didn't even report who was on the study drug mono. If they were seriously studying the drug interactions they would have measured amyloid.
They are going to have to report full data at some point. If the patients have great results on an objective measure like MMSE someone should be interested.
The one thing you don't want to do is gather information quickly in an Alzheimer's trial. That might be why Prana's trial was so screwed (by some of the same people who conducted this trial BTW). The disease progresses slowly in the population they used.